While vaccines have emerged to treat a cancer caused by human papilloma virus, there is still a need for therapies to treat cancerous tissue caused by HPV. John Docherty, president of Toronto-based Helix BioPharma, tells host Bruce Japsen about his company's research and that of the biotech industry in the study and treatment of HPV, a key virus in the development of cervical cancer.
Potential Future Treatments for Human Papilloma Virus (HPV)
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
While vaccines have emerged to treat a cancer caused by human papilloma virus, there is still a need for therapies to treat cancerous tissue caused by HPV. John Docherty, president of Toronto-based Helix BioPharma, tells host Bruce Japsen about his company's research and that of the biotech industry in the study and treatment of HPV, a key virus in the development of cervical cancer.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credits
<p>Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future</p>
CME/CE
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
0.50 credits
<p>IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credits
<p>Personalizing Care Within the RCC Treatment Paradigm</p>
Clinician's Roundtable
AI and Hair Loss: Measuring Progress with Data-Driven Insights
<p>AI and Hair Loss: Measuring Progress with Data-Driven Insights</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Cardiology
NYHA FC and Finerenone Response: Clinical Trial Insights
<p><span data-contrast="auto" xml:lang="EN-US">NYHA FC and Finerenone Response: Clinical Trial Insights</span><span data-ccp-props='{"134245417":false,"335559739":0}'> </span></p>
ACC Action Center
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
<p>Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?